Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor
详细信息 查看全文
- 作者：Kenichi Ogiwara (1)
Keiji Nogami (1)
Tomoko Matsumoto (1)
Midori Shima (1) - 关键词：Hemophilia A ; Inhibitor ; aPCC ; TFPI ; Thrombin generation
- 刊名：International Journal of Hematology
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：99
- 期：5
- 页码：577-587
- 全文大小：
- 参考文献：1. Lusher JM. The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII inhibitors. Scand J Haematol. 1984;40:195-02.
2. Lusher J, Ingerslev J, Roberts H, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998;9:119-8. CrossRef
3. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109:546-1. CrossRef
4. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia. 2009;15:3-0. CrossRef
5. Stenbjerg S, Jorgensen J. Resistance to activated FIX concentrate (FEIBA). Scand J Haematol. 1977;18:421-. CrossRef
6. Fukui H, Fujimura Y, Takahashi Y, Mikami S, Yoshioka A. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titer factor VIII inhibitor. Thromb Res. 1981;22:177-4. CrossRef
7. Hayashi T, Tanaka I, Shima M, Yoshida K, Fukuda K, Sakurai Y, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia. 2004;10:397-00. CrossRef
8. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry. 1981;20:833-0. CrossRef
9. Nakahara Y, Miyata T, Hamuro T, Funatsu A, Miyagi M, Tsunasawa S, et al. Amino acid sequence and carbohydrate structure of a recombinant human tissue factor pathway inhibitor expressed in Chinese hamster ovary cells: one N-and two O-linked carbohydrate chains are located between Kunitz domains 2 and 3 and one N-linked carbohydrate chain is in Kunitz domain 2. Biochemistry. 1996;35:6450-. CrossRef
10. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol. 1997;55:183-. CrossRef
11. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33:4-5.
12. Duckers C, Simioni P, Spiezia L, Radu C, Gavasso S, Rosing J, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood. 2008;112:3615-3. CrossRef
13. Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol. 2009;90:576-2. CrossRef
14. Luu H, Ewenstein B. FEIBA? safety profile in multiple modes of clinical and home-therapy application. Haemophilia. 2004;10:10-. CrossRef
15. Maurissen LF, Castoldi E, Simioni P, Rosing J, Hackeng TM. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost. 2010;8:750-. CrossRef
16. Mori Y, Hamuro T, Nakashima T, Hamamoto T, Natsuka S, Hase S, et al. Biochemical characterization of plasma-derived tissue factor pathway inhibitor: post-translational modification of free, full-length form with particular reference to the sugar chain. J Thromb Haemost. 2009;7:111-0. CrossRef
17. Caprini JA, Traverso CI, Arcelus JI. Perspectives on thromboelastography. Semin Thromb Hemost. 1995;21:91-.
18. Váradi K, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost. 2003;1:2374-0. CrossRef
19. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2008;28:233-2. CrossRef
20. Hansen JB, Huseby KR, Huseby NE, Ezban M, Nord?y A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thromb Res. 1997;85(4):13-5.
21. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem. 1989;264:18832-.
22. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol. 2006;124:747-7. CrossRef - 作者单位：Kenichi Ogiwara (1)
Keiji Nogami (1)
Tomoko Matsumoto (1)
Midori Shima (1)
1. Department of Pediatrics, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan - ISSN：1865-3774
文摘
Some hemophilia A patients who have developed inhibitors are poorly responsive to activated prothrombin complex concentrates (aPCC) after daily dosage, but the mechanism(s) underlying this remain unknown. We examined two representative cases. In case 1, we found that changing to recombinant factor VIIa (rFVIIa) therapy was more effective, and the response to aPCC was restored within ~2?weeks. Tissue factor (TF)-triggered thrombin generation demonstrated a prolonged lag-time and decreased peak thrombin, and this impairment was focused on TF pathway inhibitor (TFPI). Plasma-free TFPI was elevated post-infusion of aPCC, while this was unaffected by rFVIIa. TFPI returned to normal range within 2-?weeks. Plasmas obtained from patients with poor or good response to aPCC (aPCC-poor or aPCC-good), and good response to rFVIIa (FVIIa-good) demonstrated that free TFPI levels are increased in both aPCC groups, but not in FVIIa-good. TFPI levels pre- and post-infusion in aPCC-poor were significantly higher than those in aPCC-good. Addition of anti-TFPI antibody to the reaction samples demonstrated a greater increase of peak thrombin in aPCC-poor compared to aPCC-good, showing the higher TFPI activity in aPCC-poor. Free TFPI contained in aPCC corresponded to the increasing levels in plasma. In conclusion, TFPI in aPCC attenuated thrombin generation, and the reduced effectiveness of therapy in these circumstances appeared to be related to TFPI activity.